Related Experiment Video
Updated: Jun 12, 2026

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
PHLPP-1 negatively regulates Akt activity and survival in the heart
Shigeki Miyamoto1, Nicole H Purcell, Jeffrey M Smith
1Department of Pharmacology, University of California, San Diego, La Jolla, CA 92093-0636, USA. smiyamoto@ucsd.edu
Insights
PHLPP-1 (PH domain leucine-rich repeat protein phosphatase-1) inhibits Akt signaling in heart cells. Blocking PHLPP-1 enhances Akt activity and provides significant cardioprotection against injury.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Cell Signaling
Background:
- PH domain leucine-rich repeat protein phosphatase-1 (PHLPP-1) dephosphorylates Akt at Ser473, inhibiting Akt signaling in cancer cells.
- The role of PHLPP-1 in cardiac physiology and cardioprotection remains uninvestigated.
Purpose of the Study:
- To investigate the role of PHLPP-1 in the heart.
- To determine if inhibiting PHLPP-1 enhances Akt signaling and provides cardioprotection.
Main Methods:
- PHLPP-1 knockdown using small interfering RNA in neonatal rat ventricular myocytes (NRVMs) and adult mouse ventricular myocytes (AMVMs).
- Generation and analysis of PHLPP-1 knockout (KO) mice.
- Assessment of Akt phosphorylation (p-Akt) at Ser473 and Thr308, Akt catalytic activity, and mitochondrial Akt signaling.
- Evaluation of cardioprotection against doxorubicin and H2O2-induced injury in vitro.
- Assessment of infarct size in isolated perfused hearts subjected to ischemia/reperfusion.
Main Results:
- PHLPP-1 knockdown in NRVMs and AMVMs potentiated Akt phosphorylation at Ser473 and increased Akt catalytic activity.
- PHLPP-1 knockdown conferred cardioprotection against doxorubicin and H2O2.
- PHLPP-1 localizes to mitochondria, and its knockdown enhanced mitochondrial Akt signaling and hexokinase-II levels.
- PHLPP-1 KO mice exhibited potentiated Akt signaling in response to agonists and during ischemia/reperfusion.
- PHLPP-1 KO hearts showed reduced infarct size following ischemia/reperfusion.
Conclusions:
- PHLPP-1 acts as an endogenous negative regulator of Akt activity and cell survival in the heart.
- Inhibition of PHLPP-1 represents a potential therapeutic strategy for enhancing cardioprotection.
Rationale:
The recently discovered PHLPP-1 (PH domain leucine-rich repeat protein phosphatase-1) selectively dephosphorylates Akt at Ser473 and terminates Akt signaling in cancer cells. The regulatory role of PHLPP-1 in the heart has not been considered.
Objective:
To test the hypothesis that blockade/inhibition of PHLPP-1 could constitute a novel way to enhance Akt signals and provide cardioprotection.
Methods And Results:
PHLPP-1 is expressed in neonatal rat ventricular myocytes (NRVMs) and in adult mouse ventricular myocytes (AMVMs). PHLPP-1 knockdown by small interfering RNA significantly enhances phosphorylation of Akt (p-Akt) at Ser473, but not at Thr308, in NRVMs stimulated with leukemia inhibitory factor (LIF). The increased phosphorylation is accompanied by greater Akt catalytic activity. PHLPP-1 knockdown enhances LIF-mediated cardioprotection against doxorubicin and also protects cardiomyocytes against H(2)O(2). Direct Akt effects at mitochondria have been implicated in cardioprotection and mitochondria/cytosol fractionation revealed a significant enrichment of PHLPP-1 at mitochondria. The ability of PHLPP-1 knockdown to potentiate LIF-mediated increases in p-Akt at mitochondria and an accompanying increase in mitochondrial hexokinase-II was demonstrated. We generated PHLPP-1 knockout (KO) mice and demonstrate that AMVMs isolated from KO mice show potentiated p-Akt at Ser473 in response to agonists. When isolated perfused hearts are subjected to ischemia/reperfusion, p-Akt in whole-heart homogenates and in the mitochondrial fraction is significantly increased. Additionally in PHLPP-1 KO hearts, the increase in p-Akt elicited by ischemia/reperfusion is potentiated and, concomitantly, infarct size is significantly reduced.
Conclusions:
These results implicate PHLPP-1 as an endogenous negative regulator of Akt activity and cell survival in the heart.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
09:18Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death
Published on: December 27, 2016
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
cAMP-dependent Protein Kinase Pathways
Amplifying Signals via Enzymatic Cascade
Regulation of Angiogenesis and Blood Supply
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...